1. Efficacy, Tolerability and Safety of Oral Eletriptan and Ergotamine plus Caffeine (Cafergot®) in the Acute Treatment of Migraine: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Comparison
- Author
-
Jan-Peter Jansen, Daniela Pitei, Hans-Christoph Diener, Timothy J. Steiner, Avinoan Reches, and Julio Pascual
- Subjects
Adult ,Male ,Agonist ,Indoles ,Pyrrolidines ,Adolescent ,medicine.drug_class ,Migraine Disorders ,Placebo ,Cephalalgia ,Double-Blind Method ,Oral administration ,Caffeine ,Ergotamine ,medicine ,Humans ,Migraine treatment ,Eletriptan ,book ,Aged ,book.periodical ,Dose-Response Relationship, Drug ,business.industry ,Middle Aged ,medicine.disease ,Tryptamines ,Serotonin Receptor Agonists ,Drug Combinations ,Sumatriptan ,Treatment Outcome ,Neurology ,Tolerability ,Migraine ,Anesthesia ,cardiovascular system ,Female ,Neurology (clinical) ,business ,medicine.drug - Abstract
Eur Neurol. 2002;47(2):99-107 The 5-HT(1B/1D/1F) agonist eletriptan, at an oral dose of 80 mg, has been shown to be more efficacious than sumatriptan 100 mg and placebo in the treatment of migraine attacks with or without aura. Another commonly prescribed oral treatment for migraine attacks is Cafergot (1 mg ergotamine tartrate with 100 mg caffeine per tablet). The efficacy, tolerability and safety of 40- and 80-mg doses of eletriptan and 2 tablets of Cafergot were compared in a double-blind, randomised, placebo-controlled, parallel-group trial involving 733 migraine patients. Patients recorded symptoms at baseline (before treatment) and 1, 2, 4 and 24 h after dosing. Headache intensity was assessed on a 4-point scale (3 = severe pain, 2 = moderate pain, 1 = mild pain, 0 = no pain). Significantly more eletriptan-treated patients (80 mg, 68%; 40 mg, 54%) than Cafergot-treated patients (33%; p
- Published
- 2002
- Full Text
- View/download PDF